# ACMG MTHFR Testing Guidance: Why Routine SNP Orders Are Discouraged

> ACMG: do not order MTHFR polymorphism testing for thrombophilia or recurrent pregnancy loss. Fortification-era evidence dismantled the old causal chain.

*Published 2026-07-10 · Updated 2026-07-10 · By Marcus Chen*

In short

**ACMG:** do **not** order MTHFR C677T/A1298C testing for routine thrombophilia or recurrent pregnancy loss evaluation, and do not cascade to relatives for those reasons. Fortification-era evidence broke the old “SNP → high homocysteine → clot/RPL” product story for common care.

Direct-to-consumer reports turned MTHFR into an identity. Medical genetics largely refused the product. This page stays on the guideline spine.

*This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.*

## What does the ACMG practice guideline actually recommend?

Hickey et al., *Genetics in Medicine* 2013 (ACMG practice guideline) concludes that MTHFR polymorphism genotyping has **minimal clinical utility** and **should not be ordered** for clinical evaluation of thrombophilia or recurrent pregnancy loss, and should not be ordered for at-risk family members. See the [Genetics in Medicine publication](https://www.nature.com/articles/gim2012165) and [PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/23288205/). CAP laboratory education modules align: testing is not recommended for those routine indications.

  ACMG-aligned teaching points (common SNPs)
  TopicGuideline-aligned message

    Routine thrombophilia panelDo not include MTHFR SNPs
    Recurrent pregnancy loss panelDo not order MTHFR SNPs routinely
    Family cascade for SNPsNot indicated for these reasons
    677TT + normal tHcyReassure on VTE/RPL risk from MTHFR alone
    Oral contraceptivesNo known contraindication from MTHFR SNPs alone
    NTD prevention toolFolic acid—not genotype marketing

## Why did the old causal chain fail?

The historical hypothesis—reduced enzyme activity → mild hyperhomocysteinemia → venous thromboembolism, coronary disease, and recurrent pregnancy loss—did not hold as a routine clinical action pathway under modern meta-analyses and fortification-era epidemiology. North American VTE associations with 677TT largely disappeared post–folic acid fortification; residual signals are more visible in low-folate regions. Genotypes generally framed as unlikely to be clinically significant include 677 CT heterozygotes, 1298 CC homozygotes, and many compound heterozygotes in guideline discussion.

Even where 677TT plus elevated total homocysteine showed modest historical associations (VTE OR ~1.27; RPL pooled risk ~2.7 in guideline-cited figures), these are not classic high-risk thrombophilia effect sizes. Maternal 677TT and offspring neural-tube-defect odds ratios around ~1.6 still leave absolute risks low; **folic acid** remains the prevention tool.

## How should existing results be counseled?

- Name the variants as common polymorphisms, not rare metabolic disease (unless true severe deficiency is in play).

- Optional fasting total homocysteine for phenotype context in 677TT.

- Do not escalate anticoagulation solely for MTHFR SNPs.

- Audit symptom misattribution—send clots, RPL, and neuropathy to proper specialty pathways.

- Preserve evidence-based folate intake for pregnancy prevention goals; do not fear-monger folic acid.

## How does this page differ from a full MTHFR pillar?

Network pillar coverage can survey enzyme biochemistry, riboflavin, and supplement debates. This deep dive isolates the **ACMG testing utility decision**—the highest-leverage clinical gate—so readers can exit the testing funnel without waiting for a longer essay.

## What should careful readers do with this evidence?

Use primary sources linked in this article before changing household systems, training plans, or clinical conversations. Prefer measurements—lab panels, water tests, training logs, or certified product listings—over marketing claims. When evidence is observational, say so out loud: associations can guide research priorities and low-regret habits without becoming promises of disease prevention. When guidance bodies publish cutoffs or MCLs, treat them as the public reference layer and verify whether your situation is inside that legal or clinical scope. Re-check living agency pages because regulations and practice guidelines update. If two reputable sources disagree, dual-source the claim and prefer the document that states methods, units, and populations clearly. Finally, keep sex, age, pregnancy, and comorbidity modifiers in view whenever the underlying literature is limited to one demographic group.

Health Canon’s editorial standard ranks large controlled trials and codified regulations above single cohorts; cohorts above mechanism speculation; marketing last. The goal of densifying this topic cluster is enough depth that a reader can act without outsourcing judgment to a headline. If you only remember one habit from this page, make it the habit of asking for units, sample, and maintenance or adherence conditions before trusting a number.

## What should careful readers do with this evidence?

Use primary sources linked in this article before changing household systems, training plans, or clinical conversations. Prefer measurements—lab panels, water tests, training logs, or certified product listings—over marketing claims. When evidence is observational, say so out loud: associations can guide research priorities and low-regret habits without becoming promises of disease prevention. When guidance bodies publish cutoffs or MCLs, treat them as the public reference layer and verify whether your situation is inside that legal or clinical scope. Re-check living agency pages because regulations and practice guidelines update. If two reputable sources disagree, dual-source the claim and prefer the document that states methods, units, and populations clearly. Finally, keep sex, age, pregnancy, and comorbidity modifiers in view whenever the underlying literature is limited to one demographic group.

Health Canon’s editorial standard ranks large controlled trials and codified regulations above single cohorts; cohorts above mechanism speculation; marketing last. The goal of densifying this topic cluster is enough depth that a reader can act without outsourcing judgment to a headline. If you only remember one habit from this page, make it the habit of asking for units, sample, and maintenance or adherence conditions before trusting a number.

## Sources

1. [ACMG practice guideline: lack of evidence for MTHFR polymorphism testing](https://www.nature.com/articles/gim2012165)
2. [ACMG MTHFR guideline abstract](https://pubmed.ncbi.nlm.nih.gov/23288205/)
3. [CAP MTHFR educational module](https://documents.cap.org/documents/MTHFR_Full-Module.pdf)
4. [ACMG guideline addendum pathway](https://pubmed.ncbi.nlm.nih.gov/32533132/)

---
Source: https://healthcanon.com/hormones-and-genes/acmg-mthfr-testing-guidance
Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt